Two Top Researchers find Breakthrough Discoveries using Predictive Oncology’s Wholly Owned Subsidiary, TumorGenesis’s Tec...
February 17 2021 - 7:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that the products of its wholly owned subsidiary,
TumorGenesis, aided researchers in the understanding of how ovarian
cancer cells migrate outside the abdominal cavity. The research,
completed by a top-tier laboratory in Massachusetts, used
TumorGenesis’s media to capture, culture, and identify how these
cells ‘break through’ the protective lining in the abdomen, called
the omentum or abdominal membrane.
This discovery means that drugs could be targeted against that
receptor site of the omentum or lining to effectively ‘block’ the
metastasis of re-occurring ovarian cancer. Nearly 64% of women die
from ovarian cancer in the US. The current patient population has
over 21,400 new cases with nearly 13,700 dying per year, mostly
from re-occurring tumors.
The second big breakthrough was done by another topflight
researcher in the UK that used the media to isolate, identify and
study a mechanism for treatment for some ovarian cancer patients.
The treatment, a PARP inhibitor, inhibits the enzyme that in cancer
cells repairs damaged DNA. This treatment sometimes accelerates the
metastasis, often killing the patient.
By successfully growing the cell lines used for the treatment,
the researchers found a defective enzyme that can be easily blocked
by a class of compounds called PARGs (poly (ADP-ribose)
glycohydrolase). If the enzymes are blocked, the patients treated
are expected to then have a positive response to continued
PARP-PARG treatment.
“Both targets of the research aided by TumorGenesis’s
technology, blocking the omentum penetration and blocking the
enzyme that accelerates a response to PARP treatment, once
developed and approved, represent several billion dollars in future
revenues for biotech or pharma companies. Three currently available
PARP inhibitors, each becoming resistant to ovarian cancer over
time, generate $2.8 billion in revenue for such companies. That is
why TumorGenesis is expanding its product lines, offering services,
and helping pharma, biotech, and researchers around the world to
unravel cancer’s mysteries,” said CEO Dr. Carl Schwartz.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates
through three segments (Skyline, Helomics and Soluble Biotech),
which contain four subsidiaries: Helomics, TumorGenesis, Skyline
Medical and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify forward-
looking statements, although not all forward-looking statements
contain these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements because of a variety of factors including, among other
things, factors discussed under the heading “Risk Factors” in our
filings with the SEC. Except as expressly required by law, the
Company disclaims any intent or obligation to update these
forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2024 to May 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From May 2023 to May 2024